Compare Organon & Co. Common Stock (OGN) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Sprott Uranium Miners ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Sprott Uranium Miners ETF trades at $42.19 (market cap $1.78B). The key difference: Organon & Co. Common Stock is far larger — about 2× Sprott Uranium Miners ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Sprott Uranium Miners ETF for 62 Days on average.
| OGN | URNM | |
|---|---|---|
Market Cap | $3.62B | $1.78B |
Volume | 2,892,999 | 1,008,269 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $13.81 | $83.99 |
52-Week Low | $5.70 | $42.42 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
URNM trades at $44.51, down 1.44% on the day, with a bearish technical signal from moving averages and oscillators. Recent news highlights uranium's role in AI energy demand and nuclear expansion, but financial ratios are unavailable. The ETF tracks uranium miners, with support at $43 and resistance at $46.
Long-term prospects are supported by nuclear energy growth and AI power needs, but short-term price volatility and lack of fundamental data pose risks. Investor sentiment is mixed, with bullish articles on uranium's future but technical indicators suggesting caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
